TBRG is no longer a pure short-interest or earnings story. IKS Health agreed to acquire the Alabama-based healthcare IT company in a deal worth roughly $565 million, announced on April 28. That single event explains almost everything that happened to the stock this week.
The price tells the story plainly. TBRG closed at $25.73 on April 29, up 12.5% on the week and 83% over the past month. The surge began well before the formal announcement — the stock started moving in March — but the deal confirmation locked in the re-rating. With the mean analyst price target now sitting at $26.25 from the two most recent coverage actions, the stock is trading almost exactly at where the Street expects it to end up. There is very little spread left to capture.
The analyst community pivoted sharply the same day the deal landed. Both Cantor Fitzgerald and Freedom Capital Markets downgraded TBRG on April 24 — Cantor moving from Overweight to Neutral while simultaneously raising its target to $26.25, and Freedom Capital Markets dropping from Buy to Hold with a matching $26.25 target. That is not a bearish move on the business; it is the standard merger-arbitrage re-rating. Once a deal price is set, "Overweight" becomes meaningless. The six-analyst consensus now clusters entirely at Hold, with no remaining Buy ratings. Stephens had already trimmed its Equal-Weight target to $18 in early April — well before the deal — reflecting genuine operational caution at that point. That target is now stale and should be disregarded.
Short interest has been declining sharply into the deal. SI % of free float dropped from a peak of roughly 9.2% in mid-April to 7.9% by April 28 — a near-10% reduction in borrowed shares over the week alone. That unwind is consistent with short sellers covering against a fixed acquisition price: there is limited upside to holding a short when a floor is set. The borrow market reflects the same dynamic. Cost to borrow eased to 0.55% — well below elevated levels from earlier in the year — and availability has loosened as covering accelerates. The ORTEX short score has also fallen materially, dropping from 60.8 on April 15 to 50.4 by April 28, the lowest reading in the recent window. That move signals the short-side pressure that built through March and early April is now deflating.
Options positioning corroborates the M&A dynamic. The put/call ratio has collapsed from above 1.0 in the week of April 20 to 0.38 now — a sharp swing from defensive hedging toward call-side positioning. That shift likely reflects arbitrageurs and event-driven traders buying calls or unwinding put protection once the deal terms became known. The PCR is now slightly below its 20-day average of 0.43, and the z-score is essentially flat at -0.14. There is no meaningful skew remaining in either direction.
The institutional register adds useful colour. Two of the largest holders — Ocho Investments at 7.7% and Rorema Beheer at 6.6% — are named in the deal advisory filings, with Willkie advising Ocho directly. Nellore Capital Management added 574,000 shares through Q4 2025, building to a 6.3% stake. Paradigm Capital increased its holding by 216,000 shares over the same period. These are not passive index positions — several of the significant holders appear to have been active participants in engineering or supporting the transaction.
Earnings are still on the calendar for May 7, but Q1 results now matter far less than they would in a normal quarter. The deal still requires shareholder approval and regulatory clearance, and at least two M&A litigation firms have already announced investigations into whether shareholders are receiving fair value. What to watch next is straightforward: the spread between the current share price and the final acquisition price, the pace of any remaining short covering, and whether the shareholder litigation firms attract enough momentum to complicate the timeline.
See the live data behind this article on ORTEX.
Open TBRG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
